Rizatriptan

Rizatriptan
Clinical data
Trade names	Maxalt, Maxalt-MLT, Rizafilm, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601109
License data	US DailyMed: Rizatriptan;
Pregnancy; category	AU: B1;
Routes of; administration	By mouth
Drug class	Triptan
ATC code	N02CC04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) / S3; CA: ℞-only; US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	By monoamine oxidase
Elimination half-life	2–3 hours
Excretion	82% urine; 12% feces
Identifiers
	IUPAC name N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine;
CAS Number	145202-66-0 ;
PubChem CID	5078;
IUPHAR/BPS	51;
DrugBank	DB00953 ;
ChemSpider	4900 ;
UNII	WR978S7QHH;
KEGG	D00675 ;
ChEBI	CHEBI:48273 ;
ChEMBL	ChEMBL905 ;
CompTox Dashboard (EPA)	DTXSID2023565 ;
ECHA InfoCard	100.243.719
Chemical and physical data
Formula	C15H19N5
Molar mass	269.352 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1cncn1Cc2cc3c(cc2)[nH]cc3CCN(C)C;
	InChI InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 ; Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches. It is taken by mouth. It can also be applied on the tongue. It is a serotonin (5-HT) 1B/1D receptor agonist (triptan).

Common side effects include chest pain, dizziness, dry mouth, and tingling. Other side effects may include myocardial infarction, stroke, high blood pressure, serotonin syndrome, and anaphylaxis. Excessive use may result in medication overuse headaches. Use is not recommended during pregnancy and breastfeeding is not recommended within 24 hours after taking a dose. Rizatriptan is in the triptan class and is believed to work by activating the 5-HT₁ receptor.

Rizatriptan was patented in 1991 and came into medical use in 1998. It is available as a generic medication. In 2022, it was the 190th most commonly prescribed medication in the United States, with more than two million prescriptions. Rizatriptan is available in combination with meloxicam as meloxicam/rizatriptan.